Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 136

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

The DWORF micropeptide enhances contractility and prevents heart failure in a mouse model of dilated cardiomyopathy

Makarewich, Catherine A, Munir, Amir Z, Schiattarella, Gabriele G, Bezprozvannaya, Svetlana, Raguimova, Olga N, Cho, Ellen E, Vidal, Alexander H, Robia, Seth L, Bassel-Duby, Rhonda, Olson, Eric N · 2018 · eLife

Abstract

Calcium (Ca2+) dysregulation is a hallmark of heart failure and is characterized by impaired Ca2+ sequestration into the sarcoplasmic reticulum (SR) by the SR-Ca2+-ATPase (SERCA). We recently discovered a micropeptide named DWORF (DWarf Open Reading Frame) that enhances SERCA activity by displacing phospholamban (PLN), a potent SERCA inhibitor. Here we show that DWORF has a higher apparent binding affinity for SERCA than PLN and that DWORF overexpression mitigates the contractile dysfunction associated with PLN overexpression, substantiating its role as a potent activator of SERCA. Additionally, using a well-characterized mouse model of dilated cardiomyopathy (DCM) due to genetic deletion of the muscle-specific LIM domain protein (MLP), we show that DWORF overexpression restores cardiac function and prevents the pathological remodeling and Ca2+ dysregulation classically exhibited by MLP knockout mice. Our results establish DWORF as a potent activator of SERCA within the heart and as an attractive candidate for a heart failure therapeutic.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7554/elife.38319

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 48

  1. Arber, 1994, Muscle LIM protein, a novel essential regulator of myogenesis, promotes myogenic differentiation, Cell, 79, 221, 10.1016/0092-8674(94)90192-9 · DOI · Paper page
  2. Arber, 1997, MLP-deficient mice exhibit a disruption of cardiac cytoarchitectural organization, dilated cardiomyopathy, and heart failure, Cell, 88, 393, 10.1016/S0092-8674(00)81878-4 · DOI · Paper page
  3. Bers, 2002, Cardiac excitation-contraction coupling, Nature, 415, 198, 10.1038/415198a · DOI · Paper page
  4. Bidwell, 2012, An Investigation of the Phospholamban-Serca Regulatory Interaction with Fluorescence Resonance Energy Transfer
  5. Bidwell, 2016, Calcium uptake in crude tissue preparation, Methods in Molecular Biology, 1377, 161, 10.1007/978-1-4939-3179-8_16 · doi:10.1007/978-1-4939-3179-8_16
  6. Cahill, 2013, Genetic cardiomyopathies causing heart failure, Circulation Research, 113, 660, 10.1161/CIRCRESAHA.113.300282 · DOI · Paper page
  7. Greenberg, 2014, Design of a phase 2b trial of intracoronary administration of AAV1/SERCA2a in patients with advanced heart failure: the CUPID 2 trial (calcium up-regulation by percutaneous administration of gene therapy in cardiac disease phase 2b), JACC. Heart failure, 2, 84, 10.1016/j.jchf.2013.09.008 · DOI · Paper page
  8. Greenberg, 2016, Prevalence of AAV1 neutralizing antibodies and consequences for a clinical trial of gene transfer for advanced heart failure, Gene Therapy, 23, 313, 10.1038/gt.2015.109 · DOI
  9. Gwathmey, 2013, Targeting sarcoplasmic reticulum calcium ATPase by gene therapy, Human Gene Therapy, 24, 937, 10.1089/hum.2013.2512 · DOI
  10. Heineke, 2005, Attenuation of cardiac remodeling after myocardial infarction by muscle LIM protein-calcineurin signaling at the sarcomeric Z-disc, PNAS, 102, 1655, 10.1073/pnas.0405488102 · DOI · Paper page
  11. Heineke, 2010, Calcineurin protects the heart in a murine model of dilated cardiomyopathy, Journal of Molecular and Cellular Cardiology, 48, 1080, 10.1016/j.yjmcc.2009.10.012 · DOI
  12. Himes, 2016, L30A mutation of phospholemman mimics effects of cardiac glycosides in isolated cardiomyocytes, Biochemistry, 55, 6196, 10.1021/acs.biochem.6b00633 · DOI
  13. Hoshijima, 2006, Reversal of calcium cycling defects in advanced heart failure toward molecular therapy, Journal of the American College of Cardiology, 48, 15, 10.1016/j.jacc.2006.06.070 · doi:10.1016/j.jacc.2006.06.070
  14. Hou, 2008, Phosphomimetic mutations increase phospholamban oligomerization and alter the structure of its regulatory complex, Journal of Biological Chemistry, 283, 28996, 10.1074/jbc.M804782200 · doi:10.1074/jbc.m804782200
  15. Hou, 2010, Relative affinity of calcium pump isoforms for phospholamban quantified by fluorescence resonance energy transfer, Journal of Molecular Biology, 402, 210, 10.1016/j.jmb.2010.07.023 · doi:10.1016/j.jmb.2010.07.023
  16. Houser, 2000, Functional properties of failing human ventricular myocytes, Trends in Cardiovascular Medicine, 10, 101, 10.1016/S1050-1738(00)00057-8 · DOI
  17. Kadambi, 1996, Cardiac-specific overexpression of phospholamban alters calcium kinetics and resultant cardiomyocyte mechanics in transgenic mice, Journal of Clinical Investigation, 97, 533, 10.1172/JCI118446 · DOI · Paper page
  18. Kawase, 2008, Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure, Journal of the American College of Cardiology, 51, 1112, 10.1016/j.jacc.2007.12.014 · DOI · Paper page
  19. Kelly, 2008, Phospholamban oligomerization, quaternary structure, and sarco(endo)plasmic reticulum calcium ATPase binding measured by fluorescence resonance energy transfer in living cells, Journal of Biological Chemistry, 283, 12202, 10.1074/jbc.M707590200 · doi:10.1074/jbc.m707590200
  20. Kho, 2011, SUMO1-dependent modulation of SERCA2a in heart failure, Nature, 477, 601, 10.1038/nature10407 · DOI · Paper page
  21. Kimura, 1998, Phospholamban domain Ib mutations influence functional interactions with the Ca2+-ATPase isoform of cardiac sarcoplasmic reticulum, Journal of Biological Chemistry, 273, 14238, 10.1074/jbc.273.23.14238 · DOI · Paper page
  22. Knöll, 2002, The cardiac mechanical stretch sensor machinery involves a Z disc complex that is defective in a subset of human dilated cardiomyopathy, Cell, 111, 943, 10.1016/S0092-8674(02)01226-6 · DOI · Paper page
  23. Kranias, 2012, Modulation of cardiac contractility by the phospholamban/SERCA2a regulatome, Circulation Research, 110, 1646, 10.1161/CIRCRESAHA.111.259754 · DOI · Paper page
  24. Lorenzen-Schmidt, 2005, Young MLP deficient mice show diastolic dysfunction before the onset of dilated cardiomyopathy, Journal of Molecular and Cellular Cardiology, 39, 241, 10.1016/j.yjmcc.2005.05.006 · DOI
  25. Luo, 1994, Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of beta-agonist stimulation, Circulation Research, 75, 401, 10.1161/01.RES.75.3.401 · DOI · Paper page
  26. Luo, 1998, Transgenic approaches to define the functional role of dual site phospholamban phosphorylation, Journal of Biological Chemistry, 273, 4734, 10.1074/jbc.273.8.4734 · DOI
  27. Luo, 2013, Mechanisms of altered Ca²⁺ handling in heart failure, Circulation research, 113, 690, 10.1161/CIRCRESAHA.113.301651 · DOI · Paper page
  28. Ly, 2007, Gene therapy in the treatment of heart failure, Physiology, 22, 81, 10.1152/physiol.00037.2006 · DOI
  29. MacLennan, 2003, Phospholamban: a crucial regulator of cardiac contractility, Nature Reviews Molecular Cell Biology, 4, 566, 10.1038/nrm1151 · DOI · Paper page
  30. Maron, 2006, Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention, Circulation, 113, 1807, 10.1161/CIRCULATIONAHA.106.174287 · DOI · Paper page
  31. McNally, 2013, Genetic mutations and mechanisms in dilated cardiomyopathy, Journal of Clinical Investigation, 123, 19, 10.1172/JCI62862 · DOI · Paper page
  32. Minamisawa, 1999, Chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy, Cell, 99, 313, 10.1016/S0092-8674(00)81662-1 · DOI · Paper page
  33. Miyamoto, 2000, Adenoviral gene transfer of SERCA2a improves left-ventricular function in aortic-banded rats in transition to heart failure, PNAS, 97, 793, 10.1073/pnas.97.2.793 · DOI · Paper page
  34. Nakayama, 2003, Cardiac-specific overexpression of a high Ca2+ affinity mutant of SERCA2a attenuates in vivo pressure overload cardiac hypertrophy, The FASEB Journal, 17, 61, 10.1096/fj.02-0474fje · doi:10.1096/fj.02-0474fje
  35. Nelson, 2014, Small open reading frames pack a big punch in cardiac calcium regulation, Circulation Research, 114, 18, 10.1161/CIRCRESAHA.113.302716 · DOI
  36. Nelson, 2016, A peptide encoded by a transcript annotated as long noncoding RNA enhances SERCA activity in muscle, Science, 351, 271, 10.1126/science.aad4076 · DOI · Paper page
  37. Piacentino, 2003, Cellular basis of abnormal calcium transients of failing human ventricular myocytes, Circulation Research, 92, 651, 10.1161/01.RES.0000062469.83985.9B · DOI · Paper page
  38. Pleger, 2013, Heart failure gene therapy: the path to clinical practice, Circulation research, 113, 792, 10.1161/CIRCRESAHA.113.300269 · DOI
  39. Prunier, 2008, Prevention of ventricular arrhythmias with sarcoplasmic reticulum Ca2+ ATPase pump overexpression in a porcine model of ischemia reperfusion, Circulation, 118, 614, 10.1161/CIRCULATIONAHA.108.770883 · DOI
  40. Recchia, 2007, Animal models of dilated cardiomyopathy for translational research, Veterinary Research Communications, 31, 35, 10.1007/s11259-007-0005-8 · DOI
  41. Robia, 2007, Förster transfer recovery reveals that phospholamban exchanges slowly from pentamers but rapidly from the SERCA regulatory complex, Circulation Research, 101, 1123, 10.1161/CIRCRESAHA.107.159947 · doi:10.1161/circresaha.107.159947
  42. Rockman, 1998, Expression of a beta-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice, PNAS, 95, 7000, 10.1073/pnas.95.12.7000 · DOI · Paper page
  43. Sato, 2001, Rescue of contractile parameters and myocyte hypertrophy in calsequestrin overexpressing myocardium by phospholamban ablation, Journal of Biological Chemistry, 276, 9392, 10.1074/jbc.M006889200 · DOI
  44. Schindelin, 2012, Fiji: an open-source platform for biological-image analysis, Nature Methods, 9, 676, 10.1038/nmeth.2019 · DOI · Paper page
  45. Trost, 2002, Overexpression of the sarcoplasmic reticulum Ca(2+)-ATPase improves myocardial contractility in diabetic cardiomyopathy, Diabetes, 51, 1166, 10.2337/diabetes.51.4.1166 · DOI · Paper page
  46. Vangheluwe, 2006, New perspectives on the role of SERCA2's Ca2+ affinity in cardiac function, Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1763, 1216, 10.1016/j.bbamcr.2006.08.025 · DOI
  47. Zak, 2017, Regulation of focal adhesion kinase through a direct interaction with an endogenous inhibitor, Biochemistry, 56, 4722, 10.1021/acs.biochem.7b00616 · DOI
  48. Zolk, 2000, Decreased expression of the cardiac LIM domain protein MLP in chronic human heart failure, Circulation, 101, 2674, 10.1161/01.CIR.101.23.2674 · DOI

Cited by

See all 136

Metadata

Authors
Makarewich, C. A., Munir, A. Z., Schiattarella, G. G., Bezprozvannaya, S., Raguimova, O. N., Cho, E. E., Vidal, A. H., Robia, S. L., Bassel-Duby, R., & Olson, E. N.
Affiliations
  • Department of Molecular Biology and Hamon Center for Regenerative Science and Medicine, University of Texas Southwestern Medical Center, Dallas, United States
  • Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, United States
  • Department of Cell and Molecular Physiology, Loyola University Chicago, Maywood, United States
Venue
eLife
Published
2018-10-09
Volume
7
ISSN
2050-084X
Cited by
136
References
1
Language
en
Funders
  • National Institutes of Health (F32 (HL-129674), K99 (HL-141630), R01 (HL-092321), R01 (HL-130253), R01 (HL-138426), R01 (HD-087351), R01 (AR-067294))
  • American Heart Association (18POST34060230)
  • Welch Foundation (1–0025)
  • Fondation Leducq

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The DWORF micropeptide enhances contractility and prevents heart failure in a mouse model of dilated cardiomyopathy. https://app.cochat.ai/papers/10.7554/elife.38319
The paper
Makarewich, C. A., Munir, A. Z., Schiattarella, G. G., Bezprozvannaya, S., Raguimova, O. N., Cho, E. E., Vidal, A. H., Robia, S. L., Bassel-Duby, R., & Olson, E. N. (2018). The DWORF micropeptide enhances contractility and prevents heart failure in a mouse model of dilated cardiomyopathy. eLife. https://doi.org/10.7554/elife.38319

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.